In Autumn 2020, DOAJ will be relaunching with a new website with updated functionality, improved search, and a simplified application form. More information is available on our blog. Our API is also changing.

Hide this message

Efficiency and safety of subconjunctival injection of anti-VEGF agent – bevacizumab – in treating dry eye

Drug Design, Development and Therapy. 2015;2015(default):3043-3050


Journal Homepage

Journal Title: Drug Design, Development and Therapy

ISSN: 1177-8881 (Online)

Publisher: Dove Medical Press

LCC Subject Category: Medicine: Therapeutics. Pharmacology

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML



Jiang X

Lv H

Qiu W

Liu Z

Li X

Wang W


Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 16 weeks


Abstract | Full Text

Xiaodan Jiang,* Huibin Lv,* Weiqiang Qiu, Ziyuan Liu, Xuemin Li, Wei Wang Department of Ophthalmology, Peking University Third Hospital, Beijing, People’s Republic of China *These authors contributed equally as first authors Purpose: Dry eye is a chronic inflammatory ocular surface disease with high prevalence. The current therapies for dry eye remain to be unspecific and notcomprehensive. This study aims to explore safety and efficacy of a novel treatment – subconjunctival injection of bevacizumab – in dry eye patients.Methods: Sixty-four eyes of 32 dry eye patients received subconjunctival injection of 100 μL 25 mg/mL bevacizumab. Dry eye symptoms, signs (corrected visual acuity, intraocular pressure, conjunctival vascularity, corneal staining, tear break-up time, Marx line score, and blood pressure), and conjunctival impression cytology were evaluated 3 days before and 1 week, 1 month, and 3 months after injection.Results: Significant improvements were observed in dry eye symptoms, tear break-up time, and conjunctival vascularization area at all the visits after injection compared to the baseline (P<0.05). The density of the goblet cell increased significantly at 1 month and 3 months after injection (P<0.05). There was no visual and systemic threat observed in any patient.Conclusion: Subconjunctival injection of 100 µL 25 mg/mL bevacizumab is a safe and efficient treatment for ocular surface inflammation of dry eye disease. Keywords: anti-VEGF, bevacizumab, dry eye, ocular surface inflammation, subconjunctival